Top Story

FDA approves Yescarta, second-ever CAR T-cell therapy, for certain B-cell lymphomas

October 19, 2017

Read the Perspective from Joshua Brody, MD

The FDA approved axicabtagene ciloleucel as the first chimeric antigen receptor T-cell therapy to treat adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

Axicabtagene ciloleucel (Yescarta; Kite, Gilead) is the second chimeric antigen receptor (CAR) T-cell therapy approved by the FDA — following the approval of tisagenlecleucel T-suspension (Kymriah, Novartis) for the treatment of children and young adults with B-cell acute lymphoblastic leukemia — and the first therapy of this type approved for some non-Hodgkin lymphomas.

AACR: Advances in cancer research, medical funding allow for ‘phenomenal’ progress

October 17, 2017
Oncology leaders who participated in an American Association for Cancer Research webinar this afternoon highlighted several advances in cancer research and emphasized…

NIH collaboration aims to identify, validate immunotherapy biomarkers

October 13, 2017
NIH launched the Partnership for Accelerating Cancer Therapies, a 5-year public-private research collaboration. The $215 million effort is part of the national cancer…
Meeting News

HemOnc Today New York to highlight advances in immunotherapy, targeted treatments

October 11, 2017
HemOnc Today is pleased to announce plans for a 3-day CME meeting designed to offer expert perspectives and practical insights into the use of immunotherapy and…
More Headlines »

The Identification and Management of Immune-related Adverse Events in Patients with Cancer: Practice Essentials for Emergency Medicine Providers

This activity is supported by an educational grant from Bristol-Myers Squibb.

The incorporation of immunotherapies, especially the immune checkpoint inhibitors, into treatment regimens for patients…
More »

Baseball great Mike Schmidt became ‘concerned about dying’ after melanoma diagnosis

September 25, 2017
More »
Resource Centers
European Society for Medical Oncology Congress

European Society for Medical Oncology Congress


Combination Strategies in Melanoma Management: What’s New and What’s Next

This activity is supported by an educational grant from Genentech, Inc.

Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is…
More »